Calling consciousness an "entropic engine" points to something psychologically obvious: selfhood costs energy. Maintaining a stable "me" model across time, contexts, and internal contradictions ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

In an age of constant communication, receiving phone calls or messages from unknown numbers has become increasingly common. Whether it's a missed call from an unfamiliar number, a potential scam or a ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Recursion is using artificial intelligence and machine learning to accelerate drug research and development. The company benefits from partnerships with major tech and healthcare leaders, reaffirming ...

Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...

The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...

SALT LAKE CITY — On paper, Recursion Pharmaceuticals shouldn’t have worked. The company — or, at least, what existed at its founding in 2013 — hoped to pull data from images of healthy and diseased ...